Background Rapamycin, an immunosuppressive and antiproliferative drug, is used to
prevent neointima formation to reduce the risk of in-stent restenosis with rapamycin eluting …

Summary Background Vascular infection with Chlamydia pneumoniae might boost
inflammatory responses that play a pivotal part in neointima formation, which is the main …

BACKGROUND: Rapamycin is an immunosuppressive agent which also exhibits marked
antiproliferative properties. Rapamycin coated stents have been demonstrated to suppress …

Background: The aim of this study was to establish whether Chlamydia pneumoniae is
implicated in the development of restenosis in patients with coronary heart disease (CHD) …

This study was done to evaluate whether anti-Chlamydia pneumoniae seropositivity can be
a predictor of restenosis after coronary intervention. Recent studies indicate that latent …

Objectives: To establish the efficacy of oral rapamycin at a dose of 2 mg for 1 month at
reducing the 6-month restenosis rate after the implantation of bare metal stents. Methods: A …

BACKGROUND: Recent human trials with rapamycin-eluting stents have shown very low
restenosis rates. However, the high costs of these devices preclude their use in routine …

BACKGROUND: Elevated antibodies against Chlamydia pneumoniae have been
associated with coronary artery disease. In patients undergoing percutaneous coronary …

Background: Infection with Chlamydia pneumoniae may be involved in atherosclerosis.
Neointima proliferation after percutaneous coronary intervention (PCI) could be aggravated …

Objectives. Chlamydia pneumoniae (C. pneumoniae) has been detected in tissue from
coronary atherosclerotic vascular lesions and may be involved in the pathogenesis of …